



The Utah Society of Health-System Pharmacists Presents:
 Resident Continuing Pharmacy Education Series
 Spring 2021

Target Audience: Pharmacists, pharmacy technicians, and pharmacy students

Date/Time Location	Presenter	Title, Objectives & ACPE UAN
Tuesday, April 13th 3:30pm Zoom Only	Carlie Wilke, PharmD Mentor: <i>Ashley Bowden, PharmD, MS, BCPS</i> <i>Pharmacy Manager, Inpatient</i> <i>Operations</i> <i>University of Utah Health</i>	<p style="text-align: center;">We're Engaged! Proposals for Engaging Employees During COVID-19 (0.1CEU) #A-0167-0000-2-002-L04-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> 1. Discuss the importance of engagement 2. Recognize signs of diminished employee engagement amongst colleagues 3. Explain methods for evaluating employee engagement <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> 1. Develop approaches for discussing diminished engagement with colleagues and leaders 2. Formulate strategies to improve employee engagement 3. Evaluate the effectiveness of various tactics for increasing employee engagement
Tuesday, April 13th 4:30pm Zoom Only	Kathryn Fitton, PharmD Mentor: <i>Karen Gunning, PharmD, BCPS,</i> <i>BCACP, FCCP</i> <i>Clinical Pharmacist, Ambulatory</i> <i>Care,</i> <i>University of Utah Health</i>	<p style="text-align: center;">Bad Blood with Vaccines: Band-Aids Don't Fix Errors (0.1CEU) #A-0167-21-003- L06-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> 1. Identify appropriate administration technique for vaccines 2. Analyze the most common vaccine errors 3. Illustrate methods to prevent the most common vaccine errors 4. Develop a plan to avoid vaccine errors with the mass vaccination efforts for COVID-19 <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> 1. Identify appropriate administration technique for vaccines 2. Recognize how vaccine errors might occur 3. Evaluate solutions to ensure proper storage and administration of vaccines 4. Formulate a plan to prevent oneself from making vaccine errors
Thursday, April 15th 3:30 pm Zoom Only	Chanah Gallagher, PharmD Mentor: <i>Brandon Tritle, PharmD, BCIDP</i> <i>Clinical Pharmacist, Infectious</i> <i>Disease</i> <i>University of Utah Health</i>	<p style="text-align: center;">No More Mr. Fungi: Updates to the Antifungal Development Pipeline (0.1CEU) #A-0167-0000-21-004-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> 1. Identify the current gaps in antifungal therapy 2. Define the mechanisms of resistance utilized by fungi 3. Evaluate the utility of each investigational antifungal agent as a therapy option 4. Develop patient specific antifungal treatment regimens and recommendations <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> 1. Describe the investigational antifungal therapy options 2. Identify similarities and differences between historical antifungal formulations and investigational antifungal formulations 3. Demonstrate appropriate storage and preparation techniques required of investigational antifungal formulations

Date/Time Location	Presenter	Title, Objectives & ACPE UAN
Thursday, April 15th 4:30 pm Zoom Only	Calvin Jahng, PharmD Mentor: <i>Gary Huynh, PharmD, AAHIVP Clinical Pharmacist, Clinic 1A University of Utah Health</i>	<p style="text-align: center;">The ART of HIV/AIDS therapy: a guideline overview for the treatment and management of patients with HIV/AIDS (0.1CEU) #A-0167-0000-21-005-L02-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> 1. Interpret new data regarding dolutegravir use in pregnant patients living with HIV/AIDS 2. Distinguish characteristics that would qualify a patient for a two-drug ART regimen 3. Discuss important issues regarding immune reconstitution inflammatory syndrome when considering opportunistic infection prophylaxis <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> 1. Identify novel adverse events identified in post-marketing research of INSTIs 2. Differentiate between appropriate agents used for two-drug ART regimens 3. Recognize common agents used for opportunistic infection prophylaxis on patients' medication lists
Saturday, April 17th 9:00 am Zoom Only	Sean Christensen, PharmD Mentor: <i>David C. Young, PharmD Professor of Pharmacotherapy (Clinical), University of Utah College of Pharmacy Clinical Pharmacist, Cystic Fibrosis and Asthma, University of Utah Health</i>	<p style="text-align: center;">Is Trikafta the Trifecta in Cystic Fibrosis? A Modulator Update (0.1CEU) #A-0167-0000-21-006-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> 1. Identify different physiologic systems affected by Cystic Fibrosis 2. Interpret current literature surrounding Cystic Fibrosis (CF) modulator efficacy 3. Describe relevant adverse effects for CF modulators for patient education 4. Demonstrate the ability to select appropriate therapy for CF based on specific patient characteristics <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> 1. Recall the brand and generic names of common CF medications 2. Name common grants or programs available to help with financial aid for CF medications 3. Assess which CF medications are likely to need a test claim to ensure the patient affordability
Saturday, April 17th 10:00 am Zoom Only	Ian Lee, PharmD Mentor: <i>Jeannette Bean, PharmD, BCPS Clinical Pharmacist, St. Mark's Hospital</i>	<p style="text-align: center;">Don't Be A Pain: A Look At Opioid Sparing Acute Pain Management (0.1CEU) #A-0167-0000-21-007-L08-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> 1. Recall the pathophysiology and classification of pain 2. Outline the risks associated with opioid use in the acute setting and importance of implementing opioid sparing regimens 3. Classify different modalities used in acute pain management and review their efficacy and place in therapy 4. Analyze individual patient characteristics related to pain management 5. Select appropriate agents and implement a proper regimen for the treatment of acute pain that maximizes an opioid sparing approach <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> 1. Identify factors that may put a patient at risk of long-term opiate use 2. Compare and contrast the different drug classes used in the management of acute pain 3. Define and differentiate the classification of acute pain
Tuesday, April 20th 3:30pm Zoom Only	Sabrina Miller, PharmD Mentor: <i>Nicholas Cox, PharmD, BCACP Ambulatory Care Clinical Pharmacist, University of Utah Health</i>	<p style="text-align: center;">Insulin Affordability – The High Cost of High Blood Sugars (0.1CEU) #A-0167-0000-21-008-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> 1. Describe the considerations for initiating insulin 2. Distinguish the key differences between coupon cards and patient assistance plans 3. Develop a patient specific cost savings plan to decrease the cost of insulin <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> 1. Define insurance expenses incurred by patients 2. Identify which insulins are available over-the-counter 3. Develop a patient specific cost savings plan to decrease the cost of insulin

Date/Time Location	Presenter	Title, Objectives & ACPE UAN
Tuesday, April 20th 4:30pm Zoom Only	Diana Palandri, PharmD Mentors: <i>Paul Hinckley, PharmD, CSPI Poison Information Specialist- Pharmacist Utah Poison Control Center</i> <i>Cole Sloan, PharmD, BCPS, BCGP Clinical Pharmacist, Emergency Medicine University of Utah Health</i>	<p align="center">Easily Accessible and Easily Abused; The OTC Story (0.1CEU) #A-0167-0000-21-009-L05-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> Describe the prevalence of OTC medication abuse and misuse Identify short-term and long-term effects of OTC medication overdose Assemble resources for patients and providers regarding safe OTC medication use Compose a list of counseling points for commonly abused and misused OTC medications <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> Discuss the patient population most likely to abuse OTC medications Recognize patient behaviors that may indicate abuse or misuse Choose potential OTC medications of abuse from a patient’s medication list
Wednesday, April 21 st 3:30 pm Zoom Only	Kelsea Zucauckas, PharmD Mentors: <i>Alissa Chan, PharmD; Adrian Carlson, PharmD, BCPS; Todd Larsen, PharmD; Bhanupryia Sirandas, PharmD, BCPS; Crystal Truax, PharmD, BCPS; Clinical Pharmacist, Solid Organ Transplant University of Utah Health</i> <i>Lonnie Smith, PharmD, FAST; Specialty Pharmacy Manager, University of Utah Health</i>	<p align="center">Uncharted Territory, The Clot Thickens: Direct Oral Anticoagulants Use in Solid Organ Transplant (0.1CEU) #A-0167-0000-21-010-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> Indicate the differences in metabolism and clearance among the Direct Oral Anticoagulant Agents (DOACs) Recall the reversal agents available for Direct Oral Anticoagulant Agents (DOACs) Evaluate a solid organ transplant patient’s medication list for potential drug interactions with Direct Oral Anticoagulant Agents (DOACs) Propose a safe therapeutic plan to hold a Direct Oral Anticoagulant Agent (DOAC) prior to a transplant biopsy Recognize the evidence of Direct Oral Anticoagulant Agents (DOACs) in solid organ transplant <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> Describe the benefits of Direct Oral Anticoagulant Agents (DOACs) compared to warfarin Analyze a solid organ transplant patient’s medication list to identify urgent agents that are used to reverse Direct Oral Anticoagulant Agents (DOACs) Identify patients eligible for Direct Oral Anticoagulant Agents (DOACs) copay cards
Wednesday, April 21 st 4:30 pm Zoom Only	Kara Nazminia, PharmD Mentor: <i>Lauren Williams, PharmD, BCPS Clinical Pharmacist, Internal Medicine University of Utah Health</i>	<p align="center">Maximizing Patient Outcomes and Resources: A Review of Acute Pancreatitis Management (0.1CEU) #A-0167-0000-21-011-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> Identify common and uncommon causes of acute pancreatitis List medications that can cause drug-induced pancreatitis Recognize opportunities to maximize health system resources and patient outcomes in acute pancreatitis Evaluate current available literature regarding acute pancreatitis and GLP-1 agonist therapy Plan appropriate management of acute pancreatitis surrounding volume status, analgesia, nutrition, and local complications <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> Identify formulations of analgesic medications that may be used in the management of acute pancreatitis Recognize which insulin formulations may be used in the treatment of hypertriglyceridemia-induced acute pancreatitis Employ proper storage and handling techniques for antibiotics that may be used in the treatment of infected pancreatic necrosis

Date/Time Location	Presenter	Title, Objectives & ACPE UAN			
Thursday, April 22 nd 3:30 pm Zoom Only	Tanner Tregidga, PharmD Mentor: <i>Brian Hathaway, PharmD, BCIDP Clinical Pharmacist, Infectious Disease St. Mark's Hospital</i>	<p style="text-align: center;">COVID-19 Vaccines – How They Work, How Did We Get Here (0.1CEU) #A-0167-0000-21-012-L06-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Distinguish between different types of vaccines. 2. Describe how to store and administer the various types of COVID-19 vaccines. 3. Interpret the safety and efficacy data between the various types of COVID-19 vaccines. 4. Construct a plan to obtain, store, and administer each of the COVID-19 vaccines. </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Explain your role in the vaccination process. 2. Predict where the mRNA technology could be applied in the future. 3. Describe the distribution process of the COVID-19 vaccine. </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Distinguish between different types of vaccines. 2. Describe how to store and administer the various types of COVID-19 vaccines. 3. Interpret the safety and efficacy data between the various types of COVID-19 vaccines. 4. Construct a plan to obtain, store, and administer each of the COVID-19 vaccines.	<u>Technician Objectives:</u> 1. Explain your role in the vaccination process. 2. Predict where the mRNA technology could be applied in the future. 3. Describe the distribution process of the COVID-19 vaccine.
<u>Pharmacist Objectives:</u> 1. Distinguish between different types of vaccines. 2. Describe how to store and administer the various types of COVID-19 vaccines. 3. Interpret the safety and efficacy data between the various types of COVID-19 vaccines. 4. Construct a plan to obtain, store, and administer each of the COVID-19 vaccines.	<u>Technician Objectives:</u> 1. Explain your role in the vaccination process. 2. Predict where the mRNA technology could be applied in the future. 3. Describe the distribution process of the COVID-19 vaccine.				
Thursday, April 22 nd 4:30 pm Zoom Only	Julia Lee, PharmD Mentors: <i>Sarah Dehoney, PharmD, BCPS; Erica Marini, PharmD, MS, BCPS, Clinical Pharmacists, Neurology University of Utah Health</i>	<p style="text-align: center;">MVPs in MS: New Drugs for Multiple Sclerosis Treatment (0.1CEU) #A-0167-0000-21-013-L01-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Outline different modes of disease progression in multiple sclerosis 2. Explain the mechanism of action of new disease-modifying therapies for multiple sclerosis 3. Compare the route of administration and dosing schedules for new multiple sclerosis therapies 4. Distinguish similarities and differences in adverse effect profiles among new disease-modifying therapies for multiple sclerosis </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Identify generic names of new medications for treatment of multiple sclerosis 2. Apply appropriate storage and handling instructions for safe dispensing of new medications used for treatment of multiple sclerosis 3. Describe the role of the pharmacy technician in obtaining multiple sclerosis medication access </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Outline different modes of disease progression in multiple sclerosis 2. Explain the mechanism of action of new disease-modifying therapies for multiple sclerosis 3. Compare the route of administration and dosing schedules for new multiple sclerosis therapies 4. Distinguish similarities and differences in adverse effect profiles among new disease-modifying therapies for multiple sclerosis	<u>Technician Objectives:</u> 1. Identify generic names of new medications for treatment of multiple sclerosis 2. Apply appropriate storage and handling instructions for safe dispensing of new medications used for treatment of multiple sclerosis 3. Describe the role of the pharmacy technician in obtaining multiple sclerosis medication access
<u>Pharmacist Objectives:</u> 1. Outline different modes of disease progression in multiple sclerosis 2. Explain the mechanism of action of new disease-modifying therapies for multiple sclerosis 3. Compare the route of administration and dosing schedules for new multiple sclerosis therapies 4. Distinguish similarities and differences in adverse effect profiles among new disease-modifying therapies for multiple sclerosis	<u>Technician Objectives:</u> 1. Identify generic names of new medications for treatment of multiple sclerosis 2. Apply appropriate storage and handling instructions for safe dispensing of new medications used for treatment of multiple sclerosis 3. Describe the role of the pharmacy technician in obtaining multiple sclerosis medication access				

Registration, Info & Fees: All presentations are one hour. The cost is FREE for USHP members; otherwise, it is \$110 for pharmacists and \$25 for technicians to attend regardless of the number of hours or sessions attended. This fee can be paid online at <http://www.ushp.org>. If you are interested in joining USHP, please visit our website www.ushp.org and join online.

Virtual Meeting Information: DUE TO COVID-19, THE ENTIRE SERIES WILL BE PRESENTED VIA ZOOM. Please see the USHP website

Credit Hours: Through attending this program, up to 12.0 contact hours (0.12 CEUs) can be attained. **All participants must register** and, if applicable, pay for the series, obtain individual session CE codes, and complete evaluation surveys for each day attended. The links to these surveys are available on the USHP website and must be completed **BY MAY 1, 2021**. A participation code will be required to get credit for each day. You must register and pay for the CE Series by April 22nd 2021.

Special Accommodations: If you are in need of any special accommodation, please contact us at the addresses below a minimum of 2 days prior to the program in order to make arrangements.

Commercial Support: No commercial support was received for this program.

Questions? Emma Jones (emma.jones@hci.utah.edu), or Jennifer Bishop (Jennifer.Bishop@MountainStarHealth.com)



The Utah Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.